Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B Inhibitor, in Diffuse Cutaneous Systemic Sclerosis
Brief description of study
This study is being done to learn more about the safety of
the study drug, AVID200, and to find out more about the effects of different
study drug doses in people with scleroderma.
AVID200 is referred to as an investigational drug because it is in the
early stages of development and has not been approved by the U.S. Food and Drug
Administration, which means that it is not available to be prescribed or sold. The study drug is given intravenously (in the
vein) over 1 hour. Study drug is given
once every 2 weeks for a total of 3 doses.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Systemic Sclerosis,SSc,Scleroderma
-
Age: Between 18 Years - 90 Years
-
Gender: All
Updated on
14 Jul 2023.
Study ID: 832173
